09/09/2022at 15:28

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes

The contract manufacturer will produce Tzield, an approved treatment that delays the onset of stage 3 type 1 diabetes, for Provention Bio, which secured rights from Lilly’s partner in 2018.

For subscribers

Per Wold-Olsen will not seek re-election as GN Group's chair in March | Foto: Mik Eskestad/Jyllands-Posten/Ritzau Scanpix

Hearing health

Per Wold-Olsen's retirement is "a great loss for GN"

For subscribers

Katrine Hammer (right), chief executive officer of Philips Medisize A/S in Denmark and vice president for global innovation and development in Europe | Foto: Phillips-medisize

Medtech

US medtech group expands production in Denmark

For subscribers

Per Wold-Olsen, outgoing chairman of GN's board | Foto: Mik Eskestad

Hearing health

GN's veteran chairman to retire

For subscribers

Jesper J. Lange, co-founder and CEO of MC2 Therapeutics | Foto: Mc2 Therapeutics / Pr

Pharma & biotech

MC2 Therapeutics CEO steps down as board member

For subscribers

Foto: Sebastian Kahnert/AP/Ritzau Scanpix

Pharma & biotech

Atrogi doses first patient in diabetes study

For subscribers

AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes

The contract manufacturer will produce Tzield, an approved treatment that delays the onset of stage 3 type 1 diabetes, for Provention Bio, which secured rights from Lilly’s partner in 2018.

For subscribers

Hearing health

Per Wold-Olsen's retirement is "a great loss for GN"

An analyst reacts to the news that GN’s chair is not seeking re-election this year – ”he has been key in helping GN secure a significant position on the hearing aid market.”

For subscribers

Leo Pharma's Becki Morison urges the Danish Medicines Council to be more transparent about different committee candidates' impartiality issues. | Foto: Leo Pharma/pr

Pharma & biotech

Danish Medicines Council delays review of Leo Pharma's eczema treatment

Assessment of Leo Pharma’s tralokinumab is still dragging out at the Danish Medicines Council, which for a year has been unable to put together an expert committee due to the council’s impartiality policy. Leo Pharma calls for more transparency regarding the council’s challenges in that regard.

For subscribers

Latest news

See all

Jobs

See all jobs

Jobs

See all jobs

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Top news from MedWatch this week

Monday

Tuesday

Wednesday

Thursday

Friday

Sign up for our newsletter

Front page now

AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes

Per Wold-Olsen's retirement is "a great loss for GN"

US medtech group expands production in Denmark

GN's veteran chairman to retire

MC2 Therapeutics CEO steps down as board member

Atrogi doses first patient in diabetes study

Further reading

AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes

Per Wold-Olsen's retirement is "a great loss for GN"

Danish Medicines Council delays review of Leo Pharma's eczema treatment

Latest news

Jobs

Jobs